N/A
Completed N=32
Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults
Attention Deficit Hyperactivity Disorder · Substance Use Disorder (SUD)
Source: ClinicalTrials.gov NCT01270555 ↗
Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Feb 2011
Primary outcomePrimary: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score — 19.4 Units on a scale
Summary
The investigators propose to conduct an open study to evaluate the efficacy and tolerability of Bupropion SR using clinically relevant doses in ADHD adults with a recent history of or current substance use disorders. We hypothesize that Bupropion SR will be effective in treating ADHD in this population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score |
19.4 | — |
| PRIMARY Self-reported Weekly Substance Use |
18 | — |
| SECONDARY Clinical Global Impressions (CGI) Scale of Substance Use Disorder (SUD) Severity |
3.1 | — |
| SECONDARY Clinical Global Impressions (CGI) Scale of ADHD Severity |
3.8 | — |
| SECONDARY Hamilton Anxiety Scale (HAM-A) |
4.5 | — |
| SECONDARY Hamilton Depression Scale (HAM-D) |
4.5 | — |
| SECONDARY Beck Depression Inventory (BDI) |
3.7 | — |
Eligibility Criteria
Inclusion Criteria
- Male and female outpatients 18 years old or older, up to 60 years old.
- Patients with the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSM-IV, as manifested in clinical evaluation and confirmed by structured interview.
- Patients within the past 6 months known to abuse or to be dependent on alcohol or any drug (nicotine addiction not included)
Exclusion Criteria
- Any clinically unstable medical condition
- Clinically significant abnormal baseline laboratory values
- Mental retardation (I.Q. <75) or Organic brain disorders
- Seizure disorder
- Patients with a history or an eating disorder including anorexia or bulimia nervosa
- Pregnant or nursing females
- Patients with current bipolar disorder
- Psychotic disorder of any type
- Patients on psychotropics known to treat ADHD (i.e. stimulants, tricyclics)
- Patients receiving psychotherapy known to treat ADHD (i.e. cognitive or cognitive/behavioral psychotherapy)
- Patients demonstrating active withdrawal from substance abuse
Data sourced from ClinicalTrials.gov (NCT01270555). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.